Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2015 Nov;21(11):2023-7. doi: 10.1016/j.bbmt.2015.07.026. Epub 2015 Jul 31.

Intensive Care Utilization for Hematopoietic Cell Transplant Recipients.

Author information

1
Blood and Marrow Transplant Program, Stanford Health Care, Stanford, California.
2
Department of Medicine, Stanford Medicine, Stanford, California.
3
Patient Care Services, Stanford Medicine, Stanford, California.
4
Department of Anesthesiology, Perioperative and Pain Medicine, Stanford Medicine, Stanford, California.
5
Intensive Care Units, Stanford Medicine, Stanford, California.
6
Blood and Marrow Transplant Program, Stanford Health Care, Stanford, California. Electronic address: dtierney@stanfordhealthcare.org.

Abstract

Blood and marrow transplantation (BMT) is a potentially curative therapy for a number of malignant and nonmalignant diseases. Multiple variables, including age, comorbid conditions, disease, disease stage, prior therapies, degree of donor-recipient matching, type of transplantation, and dose intensity of the preparative regimen, affect both morbidity and mortality. Despite tremendous gains in supportive care, BMT remains a high-risk medical therapy. A critically ill BMT recipient may require transfer to an intensive care unit (ICU) and the specialized medical and nursing care that can be provided, such as mechanical ventilation and vasopressor support. Mortality for BMT recipients requiring care in an ICU is high. This paper will describe the experience of the Stanford Blood and Marrow Transplant Program in developing and implementing guidelines to maximize the benefit of intensive care for critically ill BMT recipients.

KEYWORDS:

Hematopoietic cell transplantation; Intensive care; Intensive care utilization

PMID:
26238809
DOI:
10.1016/j.bbmt.2015.07.026
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center